Use of Oral Agents and/or Insulin in the Treatment of Diabetes during Pregnancy: An Examination of Outcomes in Pregestational versus Gestational Diabetics
The management of diabetes
in pregnancy varies depending on whether the condition was first diagnosed
during pregnancy (gestational diabetes) or was diagnosed before pregnancy
(pregestational diabetes). Little has been published comparing the relative
efficacy of various oral agents for the treatment of gestational diabetes and
the reported experience with the insulin pump in pregnancy for pregestational
diabetes remains meager. We conducted a retrospective chart review of women
managed in a specialized diabetic clinic to compare the results of treatment of
gestational diabetes with oral agents, glyburide and acarbose, to those treated
with split-mixed insulin and treatment of pregestational diabetes with either
the insulin pump or conventional splitmixed insulin. Gestational diabetics
treated with split-mixed insulin were hospitalized significantly more often (p
< 0.001) than those treated with oral agents only. The incidence of several
important pregnancy complications (growth restriction, preterm labor,
preeclampsia, oligohydramnios) did not differ between groups. Pregestational
diabetics managed with an insulin pump had comparable glycemic control, as
measured by hemoglobin A1c, to those managed with split-mixed insulin. Infant
birth weights and Apgar scores were similar in each group. There were no
perinatal deaths in either group. Acarbose and glyburide showed comparable
efficacy in treating gestational diabetics. In addition, our experience adds to
the small number of pregnant women with pregestational diabetes who were
managed with an insulin pump that have been reported in the literature.
References
[1]
Chu, S.Y., Bachman, D.J., Callaghan, W.M., Whitlock, E.P., Dietz, P.M., Berg, C.J., et al. (2008) Association between Obesity during Pregnancy and Increased Use of Health Care. The New England Journal of Medicine, 358, 1444-1453.
http://dx.doi.org/10.1056/NEJMoa0706786
[2]
Narayan, K.M.V., Boyle, J.P., Thompson, T.J., Sorensen, S.W. and Williamson, D.F. (2003) Lifetime Risk for Diabetes Mellitus in the United States. JAMA, 290, 1884-1890. http://dx.doi.org/10.1001/jama.290.14.1884
[3]
Langer, O., Conway, D.L., Berkus, M.D., Xenakis, E.M.J. and Gonzales, O. (2000) A Comparison of Glyburide and Insulin in Women with Gestational Diabetes Mellitus. The New England Journal of Medicine, 343, 1134-1138.
http://dx.doi.org/10.1056/NEJM200010193431601
[4]
Nicholson, W., Bolen, S., Takacs Witkop, C., Neale, D., Wilson, L. and Bass, E. (2009) Benefits and Risks of Oral Diabetes Agents Compared with Insulin in Women with Gestational Diabetes. Obstetrics & Gynecology, 113, 193-205.
http://dx.doi.org/10.1097/AOG.0b013e318190a459
[5]
Carpenter, M.W. and Coustan, D.R. (1982) Criteria for Screening Tests for Gestational Diabetes. American Journal of Obstetrics and Gynecology, 144, 768.
[6]
Crowther, C.A., Hiller, J.E., Moss, J.R., McPhee, A.J., Jeffries, W.S. and Robinson, J.S. (2005) Effect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes. The New England Journal of Medicine, 352, 2477-2486.
http://dx.doi.org/10.1056/NEJMoa042973
[7]
Landon, M.B., Spong, C.Y., Thom, E., Carpenter, M.W., Ramin, S.M., Casey, B., et al. (2009) A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes. The New England Journal of Medicine, 361, 1339-1348.
http://dx.doi.org/10.1056/NEJMoa0902430
[8]
The HAPO Study Cooperative Research Group (2008) Hyperglycemia and Adverse Pregnancy Outcomes. The New England Journal of Medicine, 358, 1991-2002. http://dx.doi.org/10.1056/NEJMoa0707943
[9]
Rowan, J.A., Hague, W.M., Gao, W., Battin, M.R. and Moore, M.P. (2008) Metformin versus Insulin for the Treatment of Gestational Diabetes. The New England Journal of Medicine, 358, 2003-2015.
http://dx.doi.org/10.1056/NEJMoa0707193
[10]
Jacobson, G.F., Ramos, G.A., Ching, J.Y., Kirby, R.S., Ferrara, A. and Field, D.R. (2005) Comparison of Glyburide and Insulin for the Management of Gestational Diabetes in a Large Managed Care Organization. American Journal of Obstetrics and Gynecology, 193, 118-124. http://dx.doi.org/10.1016/j.ajog.2005.03.018
[11]
Tran, N.D., Hunter, S.K. and Yankowitz, J. (2004) Oral Hypoglycemic Agents in Pregnancy. Obstetrical & Gynecological Survey, 59, 456-463. http://dx.doi.org/10.1097/00006254-200406000-00024
[12]
Wollitzer, A.D., Zisser, B.A.H. and Jovanovic, L. (2010) Insulin Pumps and Their Use in Pregnancy. Diabetes Technology & Therapeutics, 12, S33-S36. http://dx.doi.org/10.1089/dia.2009.0187
[13]
Lapolla, A., Masin, M., Bruttomesso, D., Piva, I., Crepaldi, C., Tortul, C., et al. (2003) Analysis of Outcome of Pregnancy in Type 1 Diabetics Treated with Insulin Pump or Conventional Insulin Therapy. Acta Diabetologica, 40, 143-149. http://dx.doi.org/10.1007/s00592-003-0103-1
[14]
Gimenez, M., Conget, I., Nicolau, J., Pericot, A. and Levy, I. (2007) Outcome of Pregnancy in Women with Type 1 Diabetes Intensively Treated with Continuous Subcutaneous Insulin Infusion or Conventional Therapy. A Case-Control Study. Acta Diabetologica, 44, 34-37. http://dx.doi.org/10.1007/s00592-007-0239-5
[15]
Bergenstal, R.M., Tamborlane, W.V., Ahmann, A., Buse, J.B., Dailey, G., Davis, S.N., et al. (2010) Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. The New England Journal of Medicine, 363, 311-320.
http://dx.doi.org/10.1056/NEJMoa1002853